Synapse Microcurrent seals woundcare contract with NHS SBS

July 01, 2011

UK-based health technology company Synapse Microcurrent could be supplying its innovative Accel-Heal® wound management system to every NHS Trust in England. It has succeeded in its bid to be appointed onto a national Framework Agreement.

Accel-Heal® builds on the long-established link between electrical current and the body’s healing mechanisms. It is a compact, easily operated device that uses Synapse’s patented micro-current technology to make a real impact in wound management, in particular chronic venous leg ulcers. Accel-Heal® is generally used as a valuable adjunct treatment to compression bandages to significantly accelerate healing and improve patient comfort.

In 2009, independently conducted clinical trials demonstrated that
Accel-Heal® made significant reductions in wound size, exudate levels and pain in 95% of the trial patients who suffered from non-healing venous leg ulcers, with 38% achieving full closure.

The rigorous procurement exercise undertaken by NHS Shared Business Services (NHS SBS) resulted in Synapse Microcurrent being selected to feature on NHS SBS’s 2-year Innovative Wound Healing Technologies Framework Agreement. Over 50 companies competed with only 4 technologies being selected.

Accel-Heal® offered compelling evidence for its innovation, with independent supporting information, including clinical trials and health economics analysis demonstrating a QALY of – (minus) £7,696.

Through the new Framework Agreement NHS Trusts can provide patients with this life-enhancing treatment without further tendering, providing immediate access to the product and saving them time and money. The framework exercise provides assurance that Synapse Microcurrent has been assessed as able to supply products and services that fulfill NHS quality and budgetary needs, and meet all legislative requirements.

John Gildersleeve, CEO of Synapse commented:

“The acceptance of Accel-Heal® on the Framework Agreement is an endorsement not only of this remarkable product, but of the conviction we have demonstrated over a number of years in researching, developing and bringing to market a revolutionary new approach to the treatment of wounds, one that will not only have a dramatic effect on the quality of life for long-suffering chronic would patients, but also on costs.”

Kevin Pritchard, Director of Strategic Sourcing at NHS SBS said:

“The award of this new Framework Agreement realises an ambition for the organisation of partnering with suppliers who provide innovative products and services which deliver genuine advancements in care whilst contributing to cost management. With the estimated annual NHS cost of wound care at approximately £3 billion, any product which can demonstrate clear patient benefits in terms of advanced recovery, cost savings and productivity gains for the NHS is to be applauded.”

www.nhsprocurement.com/5450/Synapse-Micro_Current.aspx

Get Free Quotes
Add selected suppliers to your enquiry list.
Fill out our simple contact form.
Send your enquiry to all selected suppliers